Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The Survivin saga goes in vivo
John C. Reed
John C. Reed
View: Text | PDF
Commentary

The Survivin saga goes in vivo

  • Text
  • PDF
Abstract

Authors

John C. Reed

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Two routes to apoptosis. In the “intrinsic” cell death pathway, various ...
Two routes to apoptosis. In the “intrinsic” cell death pathway, various upstream stimuli, such as activation of p53, induce expression or activation of proapoptotic Bcl-2 family proteins (e.g., Bax, Puma, Noxa) that converge on mitochondria and induce cytochrome c release. In the cytosol, cytochrome c binds Apaf1, which activates caspase-9. In the “extrinsic” pathway, TNF-family receptors trigger caspase-8 activation. Active caspase-8 and caspase-9 cleave and activate caspase-3 and possibly other downstream effector caspases. Caspase-8 can also cleave and activate Bid, resulting in mitochondrial release of cytochrome c. Once activated, downstream caspases can also damage mitochondria, representing a potential amplification mechanism. The putative point of Survivin intervention at caspase-9 is shown. Cdc2 may be required for apoptosis suppression by Survivin. Expression of Cdc2 can be repressed by p53 in G2-phase. DD, death domain; DED, death effector domain.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts